BRIM Biotechnology, Inc.
6885.TW
Taiwan Stock Exchange20.45
TWD
+0.10
- -
ISIN
TW0006885007
Return %
Stock
S&P500
1Y
-33.71
19.43
3Y
-70.74
76.01
5Y
-11.28
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wen Qi Xu
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No.1, Alley 30 Taipei TP Taiwan, Province of China 11492
- IPO Date
- Dec 16, 2024
- Website
- brimbiotech.com
- Similar Companies
- Business
- BRIM Biotechnology, Inc. engages in bioscience research and development focused on innovative biotechnology solutions. The company develops and commercializes biologics, bioprocessing platforms, and related life science products and services for healthcare, agriculture, and industrial applications. Brim Biotech operates across discovery, development, manufacture, and commercialization stages, leveraging proprietary platforms to advance therapeutic candidates, diagnostic tools, and validated bioprocessing reagents. Main products and services - Therapeutic and diagnostic development programs: antibody, nucleic-acid, and protein therapeutics; diagnostic assays and companion diagnostics; personalized medicine solutions; target discovery and validation services; preclinical and translational research support - Bioprocessing platforms and reagents: upstream and downstream process development kits; cell culture media and feeds; purification resins and chromatography media; analytical and quality control reagents; scale-down model systems for process optimization - Platform technologies: proprietary expression systems; gene editing and synthetic biology tools; high-throughput screening platforms; computational biology analytics for design of experiments and process optimization - Contract research and development services: early-stage discovery services; preclinical pharmacology; toxicology studies; GMP-compliant process development; analytical method development and validation; regulatory support and documentation - Commercial products and kits: research-use-only bioscience reagents; validated assay kits; reference standards; specialized assay consumables Geographic operations - Headquarters located in Taipei, Taiwan - Operations and activities in Asia-Pacific region with commercial reach into North America and Europe - Global partnerships and distribution agreements to support international customers and contract research engagements Founding year - Founded in 2017 Subsidiaries and corporate relationships - Maintains strategic collaboration agreements with partner biotechnology firms and contract research organizations to expand capabilities across discovery, development, and manufacturing - Entity operates as an independent biotechnology company with potential affiliate networks and licensing arrangements to augment product and service offerings Latest major company changes - Strategic partnerships and alliances: enters co-development and research collaboration agreements with biotechnology and pharmaceutical partners to advance therapeutic programs and platform technologies - Funding rounds and corporate moves: participates in financing rounds to bolster R&D pipeline, scale manufacturing capabilities, and expand commercial operations - Product and service expansions: launches enhanced bioprocessing platforms and expanded catalog of analytical reagents; introduces new contract research services targeting early-stage discovery through GMP-compliant development - Organizational and market expansions: broadens geographic footprint with regional offices or distribution partnerships to support international customers - Operational changes: reorganizations to streamline R&D and manufacturing integration, alignment of commercial teams with global customers, and enhancement of regulatory and quality systems Industry context and business segments - Industry: Biotechnology and life sciences - Segments: Therapeutics development, diagnostic tools, bioprocessing reagents, contract research and development services, platform technologies - Target markets: pharmaceutical and biotechnology companies, academic research institutions, contract research organizations, diagnostic labs, and industrial bioprocessing collaborators Notes - Information reflects publicly available data and company disclosures as of the most recent period; please refer to official filings and Brim Biotech communications for precise terms and current status.